Background Pemphigus vulgaris (PV) is a rare autoimmune blistering condition. Treatment
typically combines corticosteroids with another immunosuppressive agent, such as …

Background Previous clinical trials have demonstrated that rituximab therapy combined with
conventional steroid-sparing therapy (SST) has increased rates of disease control for …

Background Pemphigus vulgaris (PV) is a life‐long IgG autoantibody‐mediated blistering
disease affecting the mucosal surfaces lined by the stratified epithelium (oral, nasal, genital) …

Background Mucous membrane pemphigoid (MMP) still represents a potentially life-and
sight-threatening disease. In a subset of patients with severe MMP, conventional …

Patients with refractory bullous pemphigoid (BP) achieve remission after rituximab treatment
but require high‐dose systemic corticosteroids until the remission. The aim of this …

Background Pemphigus is an autoimmune disease that is challenging to treat and has few
available therapeutic options. Recently, several studies have demonstrated that rituximab …

Objectives: Recent reports have documented swift responses in refractory pemphigus
vulgaris to rituximab, a monoclonal anti‐CD20 antibody. Nevertheless, no standard protocol …

Introduction Treatment options for autoimmune bullous diseases (AIBD) are currently limited
to corticosteroids and traditional immunomodulants and immunosuppressants that are …

Many studies have reported the outcome of rituximab use in pemphigus but studies
regarding the clinical risk factors for poor clinical outcomes or relapse are lacking. To clarify …

Rituximab is a monoclonal antibody targeting CD20 on B cells with proven efficacy for
pemphigus vulgaris, now an FDA-approved indication. Other autoimmune bullous diseases …